title: The role of recombinant factor VIIa (FVIIa) in fibrin structure in the absence of FVIII/FIX.
abstract: Patients with hemophilia have an impaired thrombin generation and therefore form loose fibrin hemostatic plugs that are easily dissolved by fibrinolysis. This prevents maintained hemostasis in these patients, resulting in a severe bleeding disorder. Recombinant (F)VIIa has been shown to enhance thrombin generation on already thrombin-activated platelets in the absence of FVIII and FIX. An efficacy rate of 80-90% has been found in hemophilia patients with inhibitors against FVIII or FIX both in association with major surgery and in the treatment of serious bleedings. In a model measuring fibrin clot permeability in a platelet-containing system described by Blombäck et al. (1994) this was demonstrated to be dependent on the concentration of FVIII and FIX. The addition of rFVIIa in concentrations of 1.9, 4.8 and 9.6 microg mL(-1) normalized fibrin clot permeability. The concentration of 1.9 microg mL(-1) of rFVIIa normalized clot permeability in this system and the higher concentrations of rFVIIa added only slightly to the effect. No further decrease in clot permeability was found when rFVIIa in a concentration of 1.9 microg mL(-1) was added to a sample with a normal concentration (100%) of FVIII or FIX. Higher concentrations of rFVIIa added to the plasma containing 100% of FVIII or FIX induced only a slight further decrease of fibrin permeability constant, arguing against any unwanted effect of extra rFVIIa on clot permeability in the case of a normal hemostasis. Furthermore, the fibrin network was studied with 3D microscopy and the loose network found in the absence of FVIII or FIX increased in density with increasing FVIII or FIX concentrations. The addition of rFVIIa to FVIII- or FIX-deficient systems altered the network structure, making the fibers thinner and more tightly packed.
authors.affiliation: Coagulation Research, Department of Surgical Sciences, Unit of Clinical Allergy Research, Karolinska Institutet, Karolinska Hospital, Stockholm, Sweden.
authors.forename: S
authors.initials: S
authors.lastname: He
authors.forename: M
authors.initials: M
authors.lastname: Blombäck
authors.forename: G
authors.initials: G
authors.lastname: Jacobsson Ekman
authors.forename: U
authors.initials: U
authors.lastname: Hedner
mesh_terms: D001777:Blood Coagulation / Q000187:drug effects; D002478:Cells, Cultured; D004305:Dose-Response Relationship, Drug; D005164:Factor IX / Q000494:pharmacology; D005167:Factor VII / Q000494:pharmacology*; D005169:Factor VIII / Q000494:pharmacology; D015942:Factor VIIa; D005337:Fibrin / Q000737:chemistry* / Q000378:metabolism; D006467:Hemophilia A / Q000188:drug therapy; D002836:Hemophilia B / Q000188:drug therapy; D006801:Humans; D008954:Models, Biological; D010539:Permeability / Q000187:drug effects; D016062:Porosity / Q000187:drug effects; D011994:Recombinant Proteins / Q000494:pharmacology*
chemical_list: D011994:Recombinant Proteins; D005167:Factor VII; D005169:Factor VIII; D005164:Factor IX; D005337:Fibrin; C103587:recombinant FVIIa; D015942:Factor VIIa